Femasys brings FemaSeed portfolio to UNC Health OB/GYN network

Femasys and UNC Health have partnered to offer in-office fertility diagnostics and intratubal insemination across the academic system's statewide OB/GYN locations.

The Biotech Times Editorial Team By The Biotech Times Editorial Team
A brightly lit, clean medical or dental treatment room features a gray examination chair and a modern white and chrome medical device with curved arms in the foreground.

Femasys (NASDAQ: FEMY) has agreed a commercial partnership with UNC Health, North Carolina's largest academic health system, to deploy its FemaSeed fertility portfolio across UNC Health's OB/GYN practice locations. The agreement gives the system's OB/GYN clinicians access to FemVue and SpermVue diagnostics alongside FemaSeed Complete, the company's in-office intratubal insemination product, which Femasys is positioning as a first-line treatment option ahead of specialist referral.

The partnership marks an early institutional win for Femasys's OB/GYN commercial initiative, which the Atlanta-based company launched in May at the ACOG Annual Clinical and Scientific Meeting. The strategy is designed to shift fertility care upstream, allowing general gynaecologists to initiate evaluation and first-line treatment rather than routing patients directly to reproductive endocrinologists.

The portfolio

FemVue uses ultrasound to assess fallopian tube patency, replacing or supplementing the more involved hysterosalpingogram procedure in some clinical settings. SpermVue offers an at-home male fertility screening option. FemaSeed Complete combines the company's intratubal insemination catheter with FemSperm, a sperm preparation product, enabling an in-office intrauterine or intratubal insemination cycle without recourse to an external fertility laboratory.

Dr John Coiner II, the UNC Health OB/GYN clinician who advocated for the adoption internally, said the geography of North Carolina made the case straightforward. "Many patients currently drive hours to see a fertility specialist," he said. "That distance becomes a barrier for many women and couples, leading some to delay or forgo care altogether."

Femasys chief executive and founder Kathy Lee-Sepsick said the collaboration would "enable more women to begin fertility care sooner with the physicians they already know and trust."

Market context

The move reflects a broader structural shift in reproductive medicine, where payers, health systems and policymakers have been pushing fertility services into primary and community-care settings to reduce costs and improve access, particularly outside metropolitan areas. Intratubal and intrauterine insemination carry substantially lower per-cycle costs than in-vitro fertilisation and are increasingly viewed as a clinically appropriate first step for patients with no identified barrier to natural conception other than unexplained infertility or mild male-factor issues.

Femasys occupies a relatively uncrowded niche: most fertility device and diagnostics companies have targeted specialist reproductive-medicine centres rather than general OB/GYN practices. The OB/GYN channel strategy has clear commercial logic, given that the specialty represents a far larger addressable base of clinic sites than fertility clinics alone. However, adoption will depend on whether reimbursement pathways are workable for community OB/GYN practices that may not have existing billing infrastructure for fertility procedures.

Beyond the FemaSeed portfolio, Femasys continues to advance FemBloc, its non-surgical permanent birth control device, through the FINALE pivotal trial in the United States. FemBloc received regulatory approvals in Europe, the UK and New Zealand in 2025 and is being commercialised in select international markets through strategic partnerships. Successful FDA approval of FemBloc would meaningfully broaden the company's commercial story, though the trial timeline was not updated in this release.

Sector

Topic

Geography